SAFC Expands ADC Capacity
SAFC Commercial, Sigma-Aldrich Corporation’s custom manufacturing services business unit, has completed the expansion of its St. Louis, Missouri facility to support commercial-scale antibody drug conjugate (ADC) manufacturing. The facility is in final validation and expected to go on line as planned in the third quarter of 2015.
Designed to meet SafeBridge Category 4 compound handling to safely accommodate usage of highly active compounds, the St. Louis expansion provides commercial-scale manufacturing capacity for ADCs and other targeted therapies. The company also expanded commercial capacity for highly active manufacturing and storage at the company's Madison, Wisconsin facility. SAFC's offers include cell-line engineering and media, linkers and payloads, along with conjugation expertise using both highly active and non-potent compounds. The St. Louis expansion complements other recent additions in ADC capabilities, including the announcement of SAFC's ADC Express service for preclinical ADC and bioconjugation services, and a collaboration with Baxter BioPharma Solutions for formulation and fill/finish services that was formed in 2014.